HCV/HBV coinfection: The dark side of <scp>DAA</scp>s treatment?

Madonia, Salvatore; Orlando, Elisabetta; Madonia, G; Cannizzaro, Marco

doi:10.1111/liv.13342

Cited by 18 publications

(15 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few cases of HBV-related hepatitis flares following HCV suppression with DAAs have been reported so far, some of them occurring in patients with isolated anti-HBc at baseline as our case. 5 To our knowledge, this is the first case describing an HBV reactivation in a patient with previous exposure to immunosuppressive treatment.…”

Section: Hcv/hbv Coinfection: the Dark Side Of Daas Treatment?mentioning

confidence: 76%

Response to Lipopolysaccharide binding protein predicts decompensated cirrhosis mortality? It is too early

Agiasotelli

Alexopoulou

Vasilieva

et al. 2017

Liver International

View full text Add to dashboard Cite

Section: Hcv/hbv Coinfection: the Dark Side Of Daas Treatment?mentioning

confidence: 76%

Response to Lipopolysaccharide binding protein predicts decompensated cirrhosis mortality? It is too early

Agiasotelli

Alexopoulou

Vasilieva

et al. 2017

Liver International

View full text Add to dashboard Cite

“…There are 5 case reports[17-21], 1 observational study[23] and 1 letter to the editor[22] that describe the HBV reactivation in HCV/HBV co-infected patients following the use of DAA regimens. The clinical characteristics of the patients involved in these studies are shown in Table 1.…”

Section: Reactivation Of Hepatitis B In Hcv Infected Patientsmentioning

confidence: 99%

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C

Αγγελετοπούλου

Konstantakis

Manolakopoulos

et al. 2017

WJG

View full text Add to dashboard Cite

The recent introduction of direct-acting antiviral drugs (DAAs) for treatment of the hepatitis C virus (HCV) has greatly improved the management of HCV for infected patients. These viral protein inhibitors act rapidly, allowing HCV clearance and increasing the sustained virological response rates. However, hepatitis B virus (HBV) reactivation has been reported in HCV/HBV co-infected patients. Hepatitis B reactivation refers to an abrupt increase in the HBV and is well-documented in patients with previously undetected HBV DNA due to inactive or resolved HBV infection. Reactivation can occur spontaneously, but in most cases, it is triggered by various factors. Reactivation can be transient, without clinical symptoms; however, it usually causes a hepatitis flare. HBV reactivation may occur regardless of HCV genotype and type of DAA regimen. HBV screening is strongly recommended for co-infected HCV/HBV patients before initiation and during DAA therapy regardless of HBV status, HCV genotype and class of DAAs used. HBV reactivation can be prevented with pretreatment screening and prophylactic treatment when necessary. Additional data are required to evaluate the underlying mechanisms of HBV reactivation in this setting.

show abstract

“…We thank Professor Madonia and colleagues for presenting this case, which highlights the clinical challenge of hepatitis B (HBV) reactivation as a consequence of hepatitis C (HCV) therapy. 1 Since the first release of the AASLD/IDSA guidance, clinicians have been encouraged to screen for similarly transmitted viruses (HIV and HBV). In those not immune to HBV, vaccination was advised.…”

Section: Hbv Reactivation After Hcv Eradication: Deja Vumentioning

confidence: 99%